Stroke is the third most common cause of death and the first cause of disability in the world. It has a significant share in both hospitalization and health expenditures in industrializedcountries (1).
Methods
The study was conducted onpatients with ischemic stroke whowere followed up by our Neurology Clinic. Ethics Committee approval was received for this study from the Ethics Committee of Sakarya University (28.02.2017-71522473/050.01.04/67). Consentwas obtained from the patients to participate in the study.
Patients diagnosedwith ischemic stroke; aged between 30 and 85 years; with thyroid and parathyroid diseases; using corticosteroid and hormone replacement therapy; withmalnutrition, cancer diagnosis, psychiatric treatment use, and chronic renal and liver diseases; without motor dysfunction due to anorthopedic discomfort, and who acknowledged their participation were included in the study.
There were 75 (31 female and 44 male) patients with ischemic stroke included in the study. While 28 patients experienced central pain within1 year after ischemic stroke, 47 (19 female and 28 male) patients did not experience central pain in 1 year following anischemic stroke. Patients were separated into two groups as thalamic and extrathalamic in terms of ischemic stroke localization.
The pain assessment of the patients was performed using the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) pain scale and the Visual Analog Scale (VAS). The life quality assessment was performedby the European Quality of Life-5 Dimensions (EQ-5D) and EQ-5D VAS. Moreover, the Beck Anxiety Inventory (BAI), the Beck Depression Inventory (BDI), and the Epworth Sleepiness Scale (ESS) were applied to the patients.
In groups with and without central pain, gender, age, and infarct location were compared. In the group with central pain, with the LANSS values <12 and ≥12 and according to the VAS values, QoL was assessed by EQ-5D and EQ-5D VAS. Among the same groups, comparisons were made by the BAI and BDI scores with the Epworth sleep score values of <11 and ≥11 (daytime sleepiness).
Statistical Analysis
The Fisher-Freeman-Halton test, independent samples t-test, oneway analysis of variance, Kruskal-Wallis H test, chi-square test, and correlation analyses were used in the assessment of data depending on the type and purpose of the characteristics. A p<0.05 was considered statistically significant. Statistical analysis was made using the Statistical Package for Social Sciences version 18.0 for Windows (IBM Inc.; Armonk, NY, USA).
Results
While the lowest age was 32 years and the highest age was 87 years, the average age in the group with central pain was 64.04±12.9 years, and the average age in the group without central pain was 62.8±13.9 years.
While 15 (53.6%) patients had thalamic infarct and 13 (46.4%) patients had extrathalamic infarct in the group with central pain, 7 (14.9%) patients had thalamic infarct and 40 (85.1%) patients had extrathalamic infarct in the group without central pain.
Gender and age distributions were found to be similar in the groups with and without central pain (p≤0.836 and p≤0.701, respectively). The rate of the cases with thalamic infarct was significantly higher in the group with central pain (p≤0.001).
There was a significant difference between the VAS average of 3.25±0.96 of the patients with LANSS<12 and the VAS average of 7.1±1.25 of the patients with LANSS≥12 in the group with central pain (p≤0.001). According to this result, the VAS severity of those with LANSS of ≥12 was higher.
As a result of the EQ-5D and EQ-5D VAS life quality assessment conducted in the group with central pain, there was a significant positive correlation between both values (p≤0.001), and both measurements indicated a statistically significant correlation in the QoL as the VAS level increased (p≤0.001 and p≤0.001, respectively). Similarly, it was identified that the QoL (EQ-5D and EQ-5D VAS) was lower in the group with LANSS≥12 thanin the group with LANSS<12 (p≤0.006 and p≤0.016, respectively) ( Table 1 ).
There was no statistically significant difference between the groups with and without CPSP in terms of the ESSpoint average (p≤0522). In the assessment performed in two separate groups as the Epworth score (daytime sleepiness condition) <11 and ≥11, there was no significant difference between the cases with and without CPSP (p≤0.744).Statistically significant data were obtained in the group with CPSP as the VAS score increased and in cases with LANSS≥12 according to the ESS (p≤0.001 and p≤0.002, respectively).When the groups with the Epworth score <11and ≥11 were compared,the daytime sleepiness rate was found to be significantly higher in the group with LANSS≥12 and as the VAS score increased (p≤0.018 and p≤0.001, respectively) ( Table 2 ).
The BAI and BDI values of the groups with and without CPSP did not indicate a significant change (p≤0.731 and p≤0.249, respectively), and the anxiety and depression levels of both groups were found to be similar. In the group with CPSP, it was identified that the anxiety level determined with the BAI scale was significantly higher in cases with LANSS≥12 thanin those with LANSS<12 (p≤0.007), and there was no significant difference in terms of the 
Discussion
Neuropathic pain is the pain that causes sensory symptoms and findings caused by a lesion in the peripheral or central nervous system or in both of them. It is divided into central and peripheral neuropathic pain. Post-stroke pain is one of the causes of central neuropathic pain (2, 3) . Although there remain some mysteries as to the pathophysiology of CPSP, it is believed to be caused by stroke in the region of the thalamus and extrathalamic areas. The thalamus is a relay station for sensory information from all over the body (10) . In our study, the patient group who had central pain after ischemic stroke was divided into two groups as thalamic and extrathalamic.
In most of the patients with stroke, central pain develops in the first month after stroke; however, it may also develop ≥6 months after stroke in some patients (11) . Patients who experienced central pain within 1 year after stroke were included in the study.
Although central pain after stroke was originally described as "thalamic pain," it is currently recognized that strokes involving the sensory tracts in various brain regions can produce pain similar to central pain (12) .
In some studies, higher pain intensities have been reported when the lesions were located in the brainstem or thalamus than in other areas; however, in another study, the symptoms and severity of CPSP in thalamic versus extrathalamic stroke did not differ (9) . Of the 75 patients with ischemic stroke,28 had CPSP in our study. The rates of the 15 (53.6%) patients with thalamic infarct were similar with the rates of the 13 (46.4%) patients with extrathalamic infarct. There were only 7 (14.9%) patients with thalamic infarct in the group of 47 patients without CPSP. In other words, thalamic lesions are observed more frequently in the group with CPSP thanin the group without CPSP (p≤0.001); moreover, the frequency of thalamic and extrathalamic lesions was found to be similar in the group. This situation will become clearer in future studies to be conducted with more patients with CPSP.
It is hard to diagnose CPSP. In this process, it is beneficial to identify pain level with pain scales, such as the VAS and Numerical Rating Scale; however, there was no scale developed especially for CPSP (7) . In our study, the pain assessment was performedusing the LANSS and VAS in the group with CPSP, and it was identified that the VAS severity was higher in the group with LANSS≥12 (p≤0.001). In other words, both tests were correlated in indicating the level of pain.
There are many studies on the fact that the presence of CPSP impairs the life quality of patients. For example, in the study conducted with 100 patients with stroke by Kılıç et al. (13) , CPSP was determined in 20 patients. While CPSP was evaluated by the LANSS, the QoL was evaluated by the Nottingham Health Profile (NHP).
Central pain was related to a significant difference in the pain parameter of the NHP (p≤0.001). In conclusion, CPSP is a complication that should not be ignored because it is not rare and has a negative impact on the QoL of patients with stroke. In a study conducted with 24 patients with CPSP, while pain was evaluated by the LANSS and VAS, the QoL was evaluated by the 36-item Short-Form Health Survey quality of life scale (SF-36 QoLS).The result showed that CPSP has a negative impact on the physical subscale score of the SF-36 QoLS in patients with stroke (9).In our study, the QoLof patients was assessed using the EQ-5D and EQ-5D VAS. In the assessments performed with both the LANSS and VAS, the level of pain and the QoLwere statistically significant. It was observed that as the severity of CPSP increased, the QoL decreased in correlation with this. This condition did not indicate any difference between thalamic and extrathalamic groups. It is a fact that central pain has a negative effect on the QoL; however, it is possible to increase theQoLof patients with a correct diagnosis and treatment.
In many studies, it has beendemonstrated that as CPSP affects the QoL, it also affects sleep quality. In the study conducted by Raffaeli et al. (14) with 601 patients with stroke with CPSP, half (50%) of the interviewed pain population could sleep in a restful way, 28.8% had some difficulty, and 21.8% could not sleep at all. A total of 199 patients were examined to identify sleep disorders in a 3-month period after cerebral infarct, and the nighttime sleep quality and excessive daytime sleepiness of the patients were evaluated by the Verran-Snyder-Halpernsleepscale and ESS. Bad nighttime sleep was reported in 88 (44.2%) patients, and excessive daytime sleepiness was reported in 28 (14.4%) patients. There was no significant relationship between post-stroke pain and post-stroke sleep disorders (15) . In a study conducted with 3732 individuals aged ≥65 years, as a result of the assessment using the Pittsburgh SleepQuality Index in cases with subjective bodily pain, it was observed that those with serious and very serious bodily pain had the highest values; moreover, higher values were identified in the group with mild bodily pain thanin the group without any bodily pain. It is known that painful syndromes cause sleep disorders. CPSP is one of the serious painful syndromes (16).
In our study, there was no statistically significant result between the groups with and without CPSP in terms of bad nighttime sleep and excessive daytime sleepiness. However, it was identified in the group with CPSP that the nighttime sleep quality decreased as the VAS score increased (p≤0.001). The nighttime sleep quality was worse in the group with LANSS 12 in the same group (p≤0.002). In the assessment conducted according to excessive daytime sleepiness, the rate was higher in the group with LANSS 12 and as the VAS score increased (p≤0.018 and p≤0.001, respectively).
In general, it is known that painful syndromes cause sleep disorders. CPSP is one of the serious painful syndromes (16) . These sleep disorders developing in patients with CPSP further deteriorate the QoL of patients.
Sleep disorders and functional disorders, such as depression and anxiety, are the important comorbid conditions accompanying CPSP (11) . In our study, depression and anxiety were found at similar rates between the groups with and without CPSP; however, in the assessment using the LANSS and VAS in the group with CPSP, it was identified that the anxiety and depression levels increased as the level of pain increased. In other words, pain appears as a condition increasing depression and anxiety and deteriorating the QoL in this regard. The importance of the diagnosis and treatment of these diseases accompanying CPSP has beenemphasized once again.
Conclusion
Central post-stroke pain is a frequently observed syndrome among post-stroke pains.In addition to our study and in many studies, it has been shown that it has a remarkable negative effect on the QoL of patients with stroke. It is important for the literature to emphasize that it is possible to improve the comfort of patients with a correct diagnosis and treatment of sleep disorders, depression, and anxiety accompanying CPSP.
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